Office-Based Methadone versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment – A Randomized Pragmatic Hybrid Effectiveness/Implementation Trial

To conduct a randomized, pragmatic hybrid type 1 effectiveness/implementation multisite (approximately 6 sites) trial to determine whether office-based methadone with pharmacy administration and/or dispensing or office-based buprenorphine results in greater treatment retention in approximately 600 patients with opioid use disorder. This trial will also identify implementation barriers, facilitators and acceptability at the patient, provider and health-systems level for office-based methadone with pharmacy administration and/or dispensing.

CTN Protocol ID: 

Principal Investigator(s)

David Fiellin, M.D.

Professor of Medicine and Public Health
Yale University School of Medicine

333 Cedar Street
P.O. Box 208056
New Haven, CT 06520
United States